Publications

• TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies.

  (Chakrabarti S, Wintheiser G, Tella SH, Oxencis C, Mahipal A.) Pharmacol Ther. 2021 Mar 02;224:107823 PMID: 33667525 SCOPUS ID: 2-s2.0-85102047484 03/06/2021

• Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

  (Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J.) Eur J Cancer. 2021 Feb;144:101-112 PMID: 33341444 PMCID: PMC7855426 12/21/2020

• The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.

  (Chakrabarti S, Xie H, Urrutia R, Mahipal A.) Cancers (Basel). 2020 09 29;12(10) PMID: 33003583 PMCID: PMC7601010 10/03/2020

• Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions.

  (Chakrabarti S, Peterson CY, Sriram D, Mahipal A.) World J Gastrointest Oncol. 2020 Aug 15;12(8):808-832 PMID: 32879661 PMCID: PMC7443846 09/04/2020

• Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.

  (Chakrabarti S, Kamgar M, Mahipal A.) Cancers (Basel). 2020 Jul 24;12(8) PMID: 32722188 PMCID: PMC7465131 07/30/2020

• Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.

  (Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A.) Oncologist. 2020 05;25(5):380-e763 PMID: 31826977 PMCID: PMC7216452 12/13/2019

• Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.

  (Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A.) J Gastrointest Oncol. 2019 Jun;10(3):554-561 PMID: 31183207 PMCID: PMC6534717 06/12/2019

• Local excision for patients with stage I anal canal squamous cell carcinoma can be curative.

  (Chakrabarti S, Jin Z, Huffman BM, Yadav S, Graham RP, Lam-Himlin DM, Lightner AL, Hallemeier CL, Mahipal A.) J Gastrointest Oncol. 2019 Apr;10(2):171-178 PMID: 31032082 PMCID: PMC6465491 04/30/2019

• Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

  (Chakrabarti S, Sara J, Lobo R, Eiring R, Finnes H, Mitchell J, Hartgers M, Okano A, Halfdanarson T, Grothey A.) Clin Colorectal Cancer. 2019 03;18(1):52-57 PMID: 30396850 11/07/2018

• How I Treat Metastatic Colorectal Cancer With Maintenance Therapies.

  (Chakrabarti S, Hubbard JM. .) Handbook of Gastrointestinal Cancers Evidence-Based Treatment and Multidisciplinary Patient Care. Bekaii-Saab T, editor. USA: Springer Publishing; 2019. Chapter 15; p.116-121.. 08/01/2019

• Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repair–Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade

  (Sakti Chakrabarti, MD; Lucas J. Huebner; Heidi D. Finnes, PharmD; Andrea Muranyi, PhD2; June Clements, MD; Shalini Singh, DNB, MD; Joleen M. Hubbard, MD; Robert R. McWilliams, MD; Kandavel Shanmugam, PhD; and Frank A. Sinicrope, MD.) JCO Precision Oncology, Vol.3; p 1-7. 06/28/2019

• 5-fluorouracil and cardiotoxicity: a review.

  (Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A.) Ther Adv Med Oncol. 2018;10:1758835918780140 PMID: 29977352 PMCID: PMC6024329 07/07/2018